T he package insert for a prescription agent is one of the primary sources for information about drugs marketed in the US and provides a template for safe and rational use. Although package inserts are based largely on data collected in premarketing trials, important safety data collected via postmarketing surveillance is often added to the insert after a drug is marketed.
When new safety data is of a significant nature, a black--box warning is added to the package insert. This section of the package insert alerts clinicians to particularly important information as designated by the FDA. Typically, black-box data pertains to adverse events, drug interactions, and restrictions for use. Notification of black-box warning additions and other safety information are posted by the FDA on the MEDWATCH Web site. 1 A recent article in JAMA reviewed the frequency and timing of ADR-related black-box warnings for newly marketed drugs between 1975 and 1999. 2 During this period, approximately 10% (56) of the 548 new chemical entities approved by the FDA acquired a new black-box warning or were withdrawn from the US market due to ADR-related data. Sixteen drugs approved between 1975 and 2000 were withdrawn from the market and 45 acquired one or more black-box warnings after approval. Half of the drug withdrawals occurred within two years after drug approval and half of the black-box additions occurred within 7 years after drug approval.
This article demonstrates something that many of us already strongly suspect-that safety data is not fully realized until a drug has been on the market and is used in a broader and more diverse population than in premarketing trials. What may be a surprise, however, is that a new drug has a 20% estimated probability of acquiring a black-box warning or being withdrawn from the market over a 25-year period.
It is essential that all health care professionals be familiar with blackbox data, because drugs with these warnings may be associated with significant risk or require specific monitoring to optimize efficacy and/or safety. Thus, the dilemma of black box warnings is multifold. How do we learn and disseminate information about blackbox data in an efficient and timely manner? How do we ensure that it remains embedded in information available at the point of patient care? Because the list of drugs with black-box warnings is numerous, should all or only some of these drugs be considered for highalert listing?
Although the FDA provides timely notification of new black-box data via its Web site and black-box data is included in several tertiary resources that summarize or present product package insert information (eg, Drug Facts and Comparisons, PDR), a listing of drugs with black-box warnings is not currently available. Such a list would be help heighten awareness of drugs with specific safety data or requirements.
Recently, a list of black-box data found in the package inserts of selected anti-infectives was published in Drug Link. 3 To further address this issue, a comprehensive list of drugs with black-box data will be published in the November 2002 issue of Hospital Pharmacy. (www. hospitalpharmacyjournal.com). This is just the first step in providing relevant drug information to practitioners.
Hospital Pharmacy is interested in hearing your thoughts and ideas on how you will use this information in your practice setting. Send your comments to hospitalpharmacy@drugfacts.com.
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